Mizuho Securities analyst Vamil Divan maintained a Buy rating on Pfizer (PFE) on April 7 and set a price target of $42.00. The company’s shares closed last Friday at $38.57.
According to TipRanks.com, Divan ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -1.9% and a 48.3% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals.
Currently, the analyst consensus on Pfizer is a Moderate Buy with an average price target of $41.50, representing a 9.6% upside. In a report issued on March 31, Cantor Fitzgerald also maintained a Buy rating on the stock with a $53.00 price target.
See today’s analyst top recommended stocks >>
Pfizer’s market cap is currently $215.1B and has a P/E ratio of 22.40. The company has a Price to Book ratio of -14.53.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Read More on PFE:
